Key Drivers
- Strong Liquidity
- Persistent Losses
- Negative Equity
AIAI Summary
AQST is now a high-risk, catalyst-driven bet on Anaphylm: improved usability data strengthens the planned Q3 2026 FDA resubmission, but approval and commercial adoption must overcome negative equity, rising debt, and persistent cash burn; investors should wait for clearer FDA validation or size exposure conservatively.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Negative Equity
AQST has strong liquidity and improving margins, but persistent losses, negative equity, rising debt, and cash burn make its financial sustainability high risk.
Price Behavior
Key Price Behavior Insights:
- •Strong upward trend
- •Breakout resistance
- •Support holding
AQST is bullish after rising ~36% last month, but with RSI near 76, wait for a confirmed break above $5.39 while $5.10–$5.16 remains key support.
Sharp ~36% rise last month increases near-term pullback risk
Sentiment & News
Key News Insights:
- •NDA Resubmission Progress
- •Positive Study Results
- •Institutional Buying
Aquestive is advancing toward a Q3 2026 Anaphylm NDA resubmission with positive study data and rising institutional interest, though wider-than-expected losses remain a near-term risk.
The updates are moderately positive for Aquestive shares, with regulatory progress likely outweighing earnings pressure if the FDA resubmission proceeds on schedule
Similar Companies in Healthcare
Other companies in the same sector with AI ratings